Sorry, Readability was unable to parse this page for content.
michigan football askew blue moon ann romney Paul Ryan Speech chris cooley chris cooley
Wednesday, July 31, 2013
Wednesday, May 15, 2013
Bill Hader's best celeb impersonations on 'SNL'
TV 
5 hours ago
NBC
Bill Hader as Charlie Sheen on "Saturday Night Live."
Bill Hader is pulling a Kristen Wiig.
The "Saturday Night Live" mainstay announced that after eight years, he's leaving the comedy sketch show and told The New York Times that Wiig's departure played a part in his own decision to leave.
Hader's exit, like Wiig's, will be a major blow to "SNL". Not only is he credited with portraying some of the show's most hysterical and off-beat characters, but he is arguably the most gifted celebrity impressionist to ever appear on "SNL." Over the years, he's depicted everyone from Franklin Roosevelt to Phil Spector with frighteningly accuracy.
Here's a look back at some of Hader's most impressive celebrity impersonations.
Vincent Price
Hader was spot-on with his portrayl of Golden Age horror-film star Vincent Price. He nailed Vinnie's distinctive creaky voice and stare during the holiday-themed skits, which poked fun at Price's horror-themed specials and movies. Hader depicted Price in six episodes, and each time he managed to capture Price's perfect blend of camp and creep.
CharlieSheen
Charlie Sheen was a common target for "SNL" jokes during his infamous 2011 breakdown, but Hader's impeccable portrayal of the actor is one of the most memorable Sheen-related skits. In this classic cold-open, Hader, as Sheen, interviews other celebrities known for getting bad press, and does a spot-on impression of the actor's intense mannerisms and gravelly voice.
JohnMayer
Hader captured John Mayer's signature blase attitude -- and not-so-hot singing face -- when he partnered with Wiig in this 2007 skit to mock the awkward relationship of Mayer and Jessica Simpson. The sketch captures the odd couple in an "intimate moment" in which Hader, as Mayer, is trying his best to relate to his girlfriend.
ClintEastwood
Hader earned rave reviews for his spoof of Clint Eastwood's "Empty Chair" speech at the 2012 Republican National Convention. Hader, as Eastwood, and his chair go on the road to bring their "high-waisted hi-jinks" to audiences across America. Eastwood himself later revealed that he enjoyed Hader's impression of him, telling E! News, "It was good. Hader has me down pretty good."
AlanAlda
Although he didn't necessarily look like "M*A*S*H" star Alan Alda, Hader's spot-on impersonation of Alda's voice more than makes up for it. Hader portrayed Alda on several episodes of "SNL" over the years, each time being more freakishly accurate than the last. In this 2011 sketch, Hader and other members of the cast appear as various celebrities whose "lost" auditions for the movie "Top Gun" surface on a 25th anniversary edition of the film. Hader's impersonation of Alda's voice and mannerisms in this skit is eerily accurate.
AlPacino
Hader impersonated Al Pacino on his very first episode of "SNL" back in 2005, and continued to imitate the "Scarface" star throughout his eight years on the show. In this sketch from last month, Hader poked fun at Pacino's tendency to portray murderers in his movies with this fake HBO commercial.
Which is your favorite celeb impression of his? Tell us in the comments!
Bosses Day 2012 Arlen Specter Winsor McCay Amanda Todd washington nationals Gary Collins bus driver uppercut
CCLT adds 3 board members - Inside Real Estate News
Highlights:
- 12-year-old Colorado Community Land Trust gets new board members.
- CCLT looking to grow its portfolio of 188 homes.
- New board members will help it expand.
Two leaders in affordable housing and a construction expert have joined the board of the non-profit Colorado Community Land Trust.
Joining the board are Jeff Martinez, Elizabeth Gundlach Neufeld and Dan Notartomaso
Martinez is president Brothers Redevelopment Inc., where he oversees housing counseling and maintenance programs for more than 2,000 households annually. Brothers Redevelopment also manages the Colorado Foreclosure Hotline, 1-877-601-4673.
Martinez also worked in public relations for the City of Aurora, Original Aurora Renewal and Kaiser Permanente.
Neufeld is the director of development for the Housing Authority for Aurora.
She had experience in real estate financing, development, management and asset management. At the housing authority, she has formed partnership with developers to acquire and develop more than 800 permanently affordable rental homes.
Notartomaso is the operations manager for BluSky Restoration Contractors Inc. In this role he oversees $25 million in construction projects. He also leads disaster response, most recently working on Hurricane Sandy repairs in New England.
The CCLT was created in 2001 to provide for sale, workforce housing at the Lowry neighborhood.
Today, it has 188 homes in its portfolio at Lowry and in other Denver neighborhoods. Homes are predominately townhomes as well as single family homes, with prices ranging from the low to high $100,000s.
The new board members provide additional expertise in construction management and home-buyer counseling, said Jane Harrington, executive director of CCLT.
?These skills will help guide us as we continue to expand our programs to neighborhoods throughout the metro area,? Harrington said.
Have a story idea or real estate tip? Contact John Rebchook at? JRCHOOK@gmail.com. InsideRealEstateNews.com is sponsored by Universal Lending, Land Title Guarantee and 8z Real Estate. To read more articles by John Rebchook, subscribe to the Colorado Real Estate Journal.
Related Posts:>Source: http://insiderealestatenews.com/2013/05/3-join-land-trust-board/
Call Of Duty Ghosts may day 747 crash lil wayne Kentucky Derby 2013 Barcelona celtics
Tuesday, May 14, 2013
First X-class solar flares of 2013
May 14, 2013 ? On May 13, 2013, the sun emitted an X2.8-class flare, peaking at 12:05 p.m. EDT. This is the the strongest X-class flare of 2013 so far, surpassing in strength the X1.7-class flare that occurred 14 hours earlier. It is the 16th X-class flare of the current solar cycle and the third-largest flare of that cycle. The second-strongest was an X5.4 event on March 7, 2012. The strongest was an X6.9 on Aug. 9, 2011.
The X2.8-class flare was also associated with a coronal mass ejection, or CME, another solar phenomenon that can send billions of tons of solar particles into space, which can potentially affect electronic systems in satellites and on the ground. The CME was not Earth-directed, but could pass NASA's STEREO-B, Messenger and Spitzer spacecraft. Their mission operators have been notified. Experimental NASA research models show that the CME left the sun at 1,200 miles per second beginning at 12:18 p.m. EDT. If warranted, operators can put spacecraft into safe mode to protect the instruments from solar material.
Solar flares are powerful bursts of radiation. Harmful radiation from a flare cannot pass through Earth's atmosphere to physically affect humans on the ground, however -- when intense enough -- they can disturb the atmosphere in the layer where GPS and communications signals travel. This disrupts the radio signals for as long as the flare is ongoing -- the radio blackout associated with this flare has since subsided.
The Impacts of Solar Flares
Some people worry that a gigantic "killer solar flare" could hurl enough energy to destroy Earth, but this is not actually possible.
"X-class" denotes the most intense flares, while the number provides more information about its strength. An X2 is twice as intense as an X1, an X3 is three times as intense, etc.
This flare erupted from an active region just out of sight over the left side of the sun, a region that will soon rotate into view. This region has produced two smaller M-class flares as well.
The May 12 flare was also associated with a coronal mass ejection, another solar phenomenon that can send billions of tons of solar particles into space, which can affect electronic systems in satellites and on the ground. Experimental NASA research models show that the CME left the sun at 745 miles per second and is not Earth-directed, however its flank may pass by the STEREO-B and Spitzer spacecraft, and their mission operators have been notified. If warranted, operators can put spacecraft into safe mode to protect the instruments from solar material. There is some particle radiation associated with this event, which is what can concern operators of interplanetary spacecraft since the particles can trip computer electronics on board.
Increased numbers of flares are quite common at the moment because the sun's normal 11-year activity cycle is ramping up toward solar maximum, which is expected in 2013. Humans have tracked the solar cycle continuously since it was discovered in 1843, and it is normal for there to be many flares a day during the sun's peak activity. The first X-class flare of the current solar cycle occurred on Feb. 15, 2011, and there have been another 15 X-class flares since, including this one. The largest X-class flare in this cycle was an X6.9 on Aug. 9, 2011.
NOAA's Space Weather Prediction Center (http://swpc.noaa.gov) is the U.S. government's official source for space weather forecasts, alerts, watches and warnings.
What is a solar flare?
For answers to these and other space weather questions, please visit the Space Weather Frequently Asked Questions page (http://www.nasa.gov/mission_pages/sunearth/spaceweather/index.html).
Source: http://feeds.sciencedaily.com/~r/sciencedaily/top_news/top_science/~3/2Btn_SQ_aFQ/130514083749.htm
pat summit brewers matt cain adastra holocaust remembrance day chesapeake energy dick clark death
Monday, May 13, 2013
NAS Lemoore Fleet and Family Support Center: June 2013 Classes
deployment assistance * financial management * resume writing * job search assistance * transition assistance * parenting classes * stress management * communication workshops * exceptional family member assistance * relocation assistance * clinical counseling * sexual assault prevention and response domestic violence advocacy * ombudsman program * IA/GSA Readiness * new parent support program
Source: http://fleetandfamilysupportcenterlemoore.blogspot.com/2013/05/june-2013-classes.html
maundy thursday Mexico vs USA Harmony Korine Battlefield 4 Summly monsanto Human Rights Campaign
Study identifies possible new acute leukemia marker, treatment target
![[ Back to EurekAlert! ]](https://lh3.googleusercontent.com/blogger_img_proxy/AEn0k_u1N9vLKAUCEHyGRK72obWTt7xGcR00RUVLm730YUcSyK1GVBC2SFc4x-F70rspAdusHSygQ1zVGL-kPZGsw62Sr0BPu9-lB7105j9D900=s0-d){kind=small}
Public release date: 13-May-2013[ | E-mail |
Share ] Contact: Darrell E. Ward
Darrell.Ward@osumc.edu
614-293-3737
Ohio State University Medical Center
COLUMBUS, Ohio A study has identified microRNA-155 as a new independent prognostic marker and treatment target in patients with acute myeloid leukemia that has normal-looking chromosomes under the microscope (that is, cytogenetically normal acute myeloid leukemia, or CN-AML).
The study was led by researchers at the Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC James). The researchers found that when microRNA-155 (miR-155) is present at abnormally high levels in CN-AML cells, patients are less likely to have a complete remission, and they experience a shorter disease-free period and shorter overall survival. The effect is independent of other known prognostic gene mutations present in the cells.
Published in the Journal of Clinical Oncology with an accompanying editorial and an "Understanding the Pathway" article, the findings suggest that miR-155 plays a pivotal role in CN-AML development, and that it could be a valuable target for the emerging class of drugs designed to inhibit microRNAs, says first author Dr. Guido Marcucci, professor of hematology, a leukemia specialist and associate director for Translational Research at the OSUCCC James. "MiR-155 would be relatively easy to measure at the time of diagnosis," Marcucci says. "We believe it will prove to be a good marker for stratifying patients according to recurrence risk and a good target for emerging compounds designed to inhibit microRNAs."
Principal investigator Dr. Clara D. Bloomfield, Distinguished University Professor and Ohio State University Cancer Scholar and Senior Advisor and William Greenville Pace III Endowed Chair in Cancer Research notes that, "Overall, our findings indicate that miR-155 expression is a strong and independent prognostic marker in CN-AML, and they provide clinical validation of data from preclinical models that support a crucial role of miR-155 in leukemia."
The researchers also note that because a molecule called NF-kB is believed to regulate miR-155, treatments that inhibit that molecule might also help patients with high miR-155 levels.
Cells use microRNA molecules to help regulate the kinds and amount of proteins they make. Abnormal levels of certain microRNAs are likely to play a key role in cancer development. Abnormally high expression of miR-155 is associated with lymphoma, aggressive chronic leukemias and certain solid tumors, and microRNA levels have been associated with patient survival.
For this study, Marcucci, Bloomfield and their colleagues analyzed bone-marrow or blood specimens from 363 CN-AML patients, 153 of whom were under age 60 and 210 were age 60 and over. All were treated on Cancer and Leukemia Group B (CALGB) clinical trials.
The researchers evaluated the association of abnormal miR-155 expression levels with clinical and molecular characteristics and with disease-free survival and overall survival.
The study's key technical findings include:
- Overall, patients with high miR-155 expression were about 50 percent less likely to achieve complete remission, and to have a 60 percent increase in the risk of death compared to patients with low miR-155 expression.
- High miR-155 expression was associated with pro-survival, proliferation and inflammatory gene activity, suggesting a pivotal role in leukemia development.
- In patients under age 60, higher miR-155 expression was associated with a lower complete response rate, and shorter disease-free survival and overall survival; in older patients, higher miR-155 expression was associated only with a lower complete response rate and shorter overall survival.
- The difference between older and younger patients may be related to differences in the intensity of consolidation therapy administered to younger versus older patients, as well as to biological differences.
###
Funding from the NIH/National Cancer Institute (grants CA101140, CA114725, CA31946, CA33601, CA16058, CA77658, CA129657 and CA140158), The Coleman Leukemia Research Foundation, the Deutsche Krebshilfe-Dr Mildred Scheel Cancer Foundation, the Pelotonia Fellowship Program and the Conquer Cancer Foundation supported this research.
Other researchers involved in this study were Klaus H. Metzeler, Stefano Volinia, Yue-Zhong Wu, Krzysztof Mrzek, Susan P. Whitman, Jason H. Mendler, Sebastian Schwind, Heiko Becker, Ann-Kathrin Eisfeld, Ramiro Garzon and Michael A. Caligiuri of The Ohio State University; Kati Maharry, Deedra Nicolet and Jessica Kohlschimdt of Ohio State and of the Alliance for Clinical Trials in Oncology Statistics and Data Center; Andrew J. Carroll of University of Alabama at Birmingham; Bayard L. Powell of Wake Forest University; Jonathan E. Kolitz of Monter Cancer Center; and Richard M. Stone of Dana Farber Cancer Institute.
The Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute strives to create a cancer-free world by integrating scientific research with excellence in education and patient-centered care, a strategy that leads to better methods of prevention, detection and treatment. Ohio State is one of only 41 National Cancer Institute (NCI)-designated Comprehensive Cancer Centers and one of only seven centers funded by the NCI to conduct both phase I and phase II clinical trials. The NCI recently rated Ohio State's cancer program as "exceptional," the highest rating given by NCI survey teams. As the cancer program's 210-bed adult patient-care component, The James is a "Top Hospital" as named by the Leapfrog Group and one of the top cancer hospitals in the nation as ranked by U.S.News & World Report.
[ | E-mail | Share ] ?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Public release date: 13-May-2013[ | E-mail |
Share ] Contact: Darrell E. Ward
Darrell.Ward@osumc.edu
614-293-3737
Ohio State University Medical Center
COLUMBUS, Ohio A study has identified microRNA-155 as a new independent prognostic marker and treatment target in patients with acute myeloid leukemia that has normal-looking chromosomes under the microscope (that is, cytogenetically normal acute myeloid leukemia, or CN-AML).
The study was led by researchers at the Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC James). The researchers found that when microRNA-155 (miR-155) is present at abnormally high levels in CN-AML cells, patients are less likely to have a complete remission, and they experience a shorter disease-free period and shorter overall survival. The effect is independent of other known prognostic gene mutations present in the cells.
Published in the Journal of Clinical Oncology with an accompanying editorial and an "Understanding the Pathway" article, the findings suggest that miR-155 plays a pivotal role in CN-AML development, and that it could be a valuable target for the emerging class of drugs designed to inhibit microRNAs, says first author Dr. Guido Marcucci, professor of hematology, a leukemia specialist and associate director for Translational Research at the OSUCCC James. "MiR-155 would be relatively easy to measure at the time of diagnosis," Marcucci says. "We believe it will prove to be a good marker for stratifying patients according to recurrence risk and a good target for emerging compounds designed to inhibit microRNAs."
Principal investigator Dr. Clara D. Bloomfield, Distinguished University Professor and Ohio State University Cancer Scholar and Senior Advisor and William Greenville Pace III Endowed Chair in Cancer Research notes that, "Overall, our findings indicate that miR-155 expression is a strong and independent prognostic marker in CN-AML, and they provide clinical validation of data from preclinical models that support a crucial role of miR-155 in leukemia."
The researchers also note that because a molecule called NF-kB is believed to regulate miR-155, treatments that inhibit that molecule might also help patients with high miR-155 levels.
Cells use microRNA molecules to help regulate the kinds and amount of proteins they make. Abnormal levels of certain microRNAs are likely to play a key role in cancer development. Abnormally high expression of miR-155 is associated with lymphoma, aggressive chronic leukemias and certain solid tumors, and microRNA levels have been associated with patient survival.
For this study, Marcucci, Bloomfield and their colleagues analyzed bone-marrow or blood specimens from 363 CN-AML patients, 153 of whom were under age 60 and 210 were age 60 and over. All were treated on Cancer and Leukemia Group B (CALGB) clinical trials.
The researchers evaluated the association of abnormal miR-155 expression levels with clinical and molecular characteristics and with disease-free survival and overall survival.
The study's key technical findings include:
- Overall, patients with high miR-155 expression were about 50 percent less likely to achieve complete remission, and to have a 60 percent increase in the risk of death compared to patients with low miR-155 expression.
- High miR-155 expression was associated with pro-survival, proliferation and inflammatory gene activity, suggesting a pivotal role in leukemia development.
- In patients under age 60, higher miR-155 expression was associated with a lower complete response rate, and shorter disease-free survival and overall survival; in older patients, higher miR-155 expression was associated only with a lower complete response rate and shorter overall survival.
- The difference between older and younger patients may be related to differences in the intensity of consolidation therapy administered to younger versus older patients, as well as to biological differences.
###
Funding from the NIH/National Cancer Institute (grants CA101140, CA114725, CA31946, CA33601, CA16058, CA77658, CA129657 and CA140158), The Coleman Leukemia Research Foundation, the Deutsche Krebshilfe-Dr Mildred Scheel Cancer Foundation, the Pelotonia Fellowship Program and the Conquer Cancer Foundation supported this research.
Other researchers involved in this study were Klaus H. Metzeler, Stefano Volinia, Yue-Zhong Wu, Krzysztof Mrzek, Susan P. Whitman, Jason H. Mendler, Sebastian Schwind, Heiko Becker, Ann-Kathrin Eisfeld, Ramiro Garzon and Michael A. Caligiuri of The Ohio State University; Kati Maharry, Deedra Nicolet and Jessica Kohlschimdt of Ohio State and of the Alliance for Clinical Trials in Oncology Statistics and Data Center; Andrew J. Carroll of University of Alabama at Birmingham; Bayard L. Powell of Wake Forest University; Jonathan E. Kolitz of Monter Cancer Center; and Richard M. Stone of Dana Farber Cancer Institute.
The Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute strives to create a cancer-free world by integrating scientific research with excellence in education and patient-centered care, a strategy that leads to better methods of prevention, detection and treatment. Ohio State is one of only 41 National Cancer Institute (NCI)-designated Comprehensive Cancer Centers and one of only seven centers funded by the NCI to conduct both phase I and phase II clinical trials. The NCI recently rated Ohio State's cancer program as "exceptional," the highest rating given by NCI survey teams. As the cancer program's 210-bed adult patient-care component, The James is a "Top Hospital" as named by the Leapfrog Group and one of the top cancer hospitals in the nation as ranked by U.S.News & World Report.
[ | E-mail | Share ] ?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Source: http://www.eurekalert.org/pub_releases/2013-05/osum-sip051313.php
michael buble michael buble Jenni Rivera Alive Facebook Down bo jackson bo jackson hanukkah
Subscribe to:
Posts (Atom)